Reply To: Traders Market Weekly: APR 3-9 — Yield Inversion & Inflation concerns

#35281
ClemSnide
Participant

BMY:

Bristol-Myers (BMY) receives European commission approval for Opdivo plus yervoy (ipilimumab) as first-line treatment for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression
Bristol-Myers (BMY) receives European commission approval for Opdivo (nivolumab) with chemotherapy as first-line treatment for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1
Bristol Myers (BMY) receives Marketing Authorization from European Commission for Breyanzi for certain forms of relapsed or refractory large B-cell lymphoma